Breaking News: Mixed Review From FDA Advisory Comittee for Alemtuzumab

The US Food and Drug Administration's (FDA's) Peripheral and Central Nervous System Drugs Advisory Committee gave the new multiple sclerosis (MS) drug alemtuzumab (Lemtrada, Genzyme) a roller coaster ride, not reaching definite conclusions at the end of the day as to whether it should be approved or not.